Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Repligen has received a Notice of Allowance from the US Patent and Trademark Office for a patent covering a recombinant form of Protein A. It is identical in structure to the commercial form of Protein A from Staphylococcus aureus, which is used in the production of several approved monoclonal antibodies.
Subscribe to our email newsletter
The company said that the patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities. The product has been developed as an alternative to the legacy Staphylococcus aureus Protein A, and will be the basis of Repligen’s future chromatography product development.
Walter Herlihy, president and CEO of Repligen, said: “This action by the patent office reflects our continuing investment and commitment to our Bioprocessing business. This recently launched recombinant Protein A product is an important step in expanding our business through both organic growth and product acquisition.”
Repligen is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.